Skip to main content
In honor of World Cancer Day on February 4, members of the Oncology Data Advisor Fellows Forum and Editorial Board joined forces for a thought-provoking discussion about improving cancer care on a global scale, including treatment access, molecular t...
Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and c...
Recently, Genmab and AbbVie announced updated results of the phase 1/2 EPCORE™ NHL-1 clinical trial of epcoritamab (epco) for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Matthew Hadfield and Dr. Alankrita Taneja of t...
Oncology Data Advisor® · Racial and Socioeconomic Disparities in the CLL Community Oncology Setting: Ira Zackon, MD At the recent 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ira Zackon, MD,...
Oncology Data Advisor® · Guiding Dietary Choices During Multiple Myeloma Treatment: Richa Parikh, MD In this interview from the 2023 American Society of Hematology Annual Meeting, Richa Parikh, MD, a third-year Hematology/Oncology Fellow a...
Oncology Data Advisor® · Highlights of Multiple Myeloma Research Presented at ASH 2023: Urvi Shah, MD At the recent American Society of Hematology (ASH) Annual Meeting, numerous updates were presented with the potential to impact practice ...
Oncology Data Advisor® has appointed Rahul Banerjee, MD, FACP, as Editor in Chief for its next term. Dr. Banerjee is an Assistant Professor of Medicine in the Division of Oncology at the University of Washington, Fred Hutchinson Cancer Center in Seat...
The FDA has approved bosutinib (Bosulif®, Pfizer) for treatment of pediatric patients with newly diagnosed or resistant/intolerant to prior therapy chronic phase (CP) Philadelphia chromosome (Ph)–positive chronic myelogenous leukemia (CML). In additi...
In the beginning of 2022, i3 Health and Oncology Data Advisor hosted ODACon: A Rare Hematologic Malignancies Symposium, a live, virtual symposium which provided five educational activities that challenged knowledge gaps experienced by clinicians rega...